Patient Enrollment Form

Once complete, submit by Fax 1-833-469-8333 or email TEPEZZAHBYS@horizontherapeutics.com

Complete all required fields, including prescriber's signature and date, to initiate patient enrollment process.

For patient support and/or assistance obtaining patient signature,

call Horizon By Your Side at 1-833-	3-1EFEZZA (1-633-363-7399).
PATIENT INFORMATION (* indicates a r	equired field)
	_
First name*	Last name*
Sex: Male Female	Date of birth*:///
Primary language	Email address
	It to leave voice message at patient O_{Yes} O_{Nc} alternate contact telephone?
0 0	it to send text message? OYes ONG
Address*	
City*	State* ZIP code*
Alternate contact name	Alternate contact telephone
DIAGNOSIS (* indicates a required field)) (Required for benefits investigation)
PRIMARY DIAGNOSIS CODE*: Please select or	ne.
E05.00 — Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm (hyperthyroidism)	Other ICD-10 code:
Clinical Activity Score (CAS):	_
Date of Thyroid Eye Disease (TED) Diagnosis	5://
Additional disease manifestation codes:	
	s a required field) (Please include front and back nsurance card[s] with this form)
Primary insurance*	Secondary insurance
Policy #*	Policy #
Policyholder's first and last name*	Policyholder's first and last name
Insurance company telephone*	Insurance company telephone
Group #*	Group #
Policyholder's Date of birth*:/_/ (MM/DD/YYYY)	Policyholder's//
(MM/DD/YYYY) Patient is uninsured to my knowledge.	(MM/DD/YYYY)
requirements such as e-prescribing, state-sp	nply with his/her state-specific prescription pecific prescription form, fax language, etc. nents could result in outreach to the prescriber.
PATIENT AUTHORIZATION (Required—ple	ease see authorization language on the next page)
>	Date: / /
Patient signature Please read page 2	Date://
Printed full name	

Please see Important Safety Information on next page and Full Prescribing Information at TEPEZZAhcp.com.



First name*	Last name*
Address*	
City*	State* ZIP code*
NPI #* Tax ID #*	State license #*
Clinic/hospital affiliation	
Office contact name*	
Office contact telephone*	Fax*
Email address*	
Preferred communication: Telephone E	mail
Prescriber's specialty:	
Referring physician: Was this patient referred	to you by another physician? Yes
Name:	Specialty:
City	State
ZIP code	Telephone
INFUSION FACILITY	
Facility address	
City	
	State ZIP code
Telephone	State ZIP code Fax
Telephone Facility NPI #	
	Fax Facility tax ID #
Facility NPI #	Fax Facility tax ID # specialty pharmacy benefit or home infusion) injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosir
Facility NPI # PRESCRIPTION INFORMATION (Required for Medication: TEPEZZA* (teprotumumab-trbw) for Duration: 1 infusion every 3 weeks for a total of 8 90 minutes. Subsequent infusions may be reduced.	Fax Facility tax ID # specialty pharmacy benefit or home infusion; injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosir ation for additional instruction. Week 3: mg (20 mg/kg)
PRESCRIPTION INFORMATION (Required for Medication: TEPEZZA* (teprotumunab-trbw) for Duration: 1 infusion every 3 weeks for a total of 8 90 minutes. Subsequent infusions may be reduce and Administration section of Prescribing Inform. Dose*: Week 0: mg (10 mg/kg)	Fax Facility tax ID # specialty pharmacy benefit or home infusion) injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosir ation for additional instruction. Week 3: mg (20 mg/kg)
PRESCRIPTION INFORMATION (Required for Medication: TEPEZZA* (teprotumumab-trbw) for Duration: 1 infusion every 3 weeks for a total of 8 90 minutes. Subsequent infusions may be reduce and Administration section of Prescribing Information (Prescribing Information) (Prescription) (Prescr	Fax Facility tax ID # specialty pharmacy benefit or home infusion) injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosir ation for additional instruction. Week 3: mg (20 mg/kg) 21-day supply; 1 prescription; 6 refills; q3wk Patient is Medically Urgent. Medically Urgent means the patient both (1) is experiencing compressive optic neuropathy secondary to Thyroid Eye Disease and (2) requires accelerated
PRESCRIPTION INFORMATION (Required for Medication: TEPEZZA* (teprotumumab-trbw) for Duration: 1 infusion every 3 weeks for a total of 8 80 minutes. Subsequent infusions may be reduce and Administration section of Prescribing Inform. Dose*: Week 0: mg (10 mg/kg) 21-day supply; 1 prescription; no refill Weight*: kg lbs Allergies*: or	Fax Facility tax ID # specialty pharmacy benefit or home infusion) injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosir ation for additional instruction. Week 3: mg (20 mg/kg) 21-day supply; 1 prescription; 6 refills; q3wk Patient is Medically Urgent. Medically Urgent means the patient both (1) is experiencing compressive optic neuropathy secondary to Thyroid Eye Disease and (2) requires accelerated treatment with TEPEZZA. No known drug allergies (NKDA)
PRESCRIPTION INFORMATION (Required for Medication: TEPEZZA* (teprotumumab-trbw) for Duration: 1 infusion every 3 weeks for a total of 8 90 minutes. Subsequent infusions may be reduce and Administration section of Prescribing Inform. Dose*: Week 0: mg (10 mg/kg) 21-day supply; 1 prescription; no refill Weight*: kg lbs Allergies*: or Route of administration: Peripheral IV Fluids for reconstitution/administration: Recons for injection, USP. Administer via an infusion bag	Facility tax ID # specialty pharmacy benefit or home infusion) injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosir ation for additional instruction. Week 3: mg (20 mg/kg) 21-day supply; 1 prescription; 6 refills; q3wk Patient is Medically Urgent. Medically Urgent means the patient both (1) is experiencing compressive optic neuropathy secondary to Thyroid Eye Disease and (2) requires accelerated treatment with TEPEZZA. No known drug allergies (NKDA) Authorize administration supplies as nee
PRESCRIPTION INFORMATION (Required for Medication: TEPEZZA* (teprotumumab-trbw) for Duration: 1 infusion every 3 weeks for a total of 8 90 minutes. Subsequent infusions may be reduce and Administration section of Prescribing Inform. Dose*: Week 0: mg (10 mg/kg)	Fax Facility tax ID # specialty pharmacy benefit or home infusion) injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosir ation for additional instruction. Week 3: mg (20 mg/kg) 21-day supply; 1 prescription; 6 refills; q3wk Patient is Medically Urgent. Medically Urgent means the patient both (1) is experiencing compressive optic neuropathy secondary to Thyroid Eye Disease and (2) requires accelerated treatment with TEPEZZA. No known drug allergies (NKDA) Authorize administration supplies as nee stitute each vial with 10 mL of sterile water g containing 0.9% sodium chloride solution, r doses ≥1800 mg, use a 250 mL bag.
PRESCRIPTION INFORMATION (Required for Medication: TEPEZZA* (teprotumumab-trbw) for Jouration: 1 infusion every 3 weeks for a total of 8 20 minutes. Subsequent infusions may be reduce and Administration section of Prescribing Inform. Dose*: Week 0:mg (10 mg/kg) 21-day supply; 1 prescription; no refill Weight*: kg lbs Allergies*: or Route of administration: Peripheral IV Fluids for reconstitution/administration: Reconstor injection, USP. Administer via an infusion bag USP. For doses <1800 mg, use a 100 mt bag. Fo	Fax Facility tax ID # specialty pharmacy benefit or home infusion) injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosir ation for additional instruction. Week 3: mg (20 mg/kg) 21-day supply; 1 prescription; 6 refills; q3wk Patient is Medically Urgent. Medically Urgent means the patient both (1) is experiencing compressive optic neuropathy secondary to Thyroid Eye Disease and (2) requires accelerated treatment with TEPEZZA. No known drug allergies (NKDA) Authorize administration supplies as nee stitute each vial with 10 mL of sterile water containing 0.9% sodium chloride solution, r doses ≥1800 mg, use a 250 m bag.
PRESCRIPTION INFORMATION (Required for Medication: TEPEZZA* (teprotumumab-trbw) for Duration: 1 infusion every 3 weeks for a total of 8 20 minutes. Subsequent infusions may be reduce and Administration section of Prescribing Inform. Dose*: Week 0:mg (10 mg/kg) 21-day supply; 1 prescription; no refill Weight*: kg lbs Allergies*: or Route of administration: Peripheral IV Fluids for reconstitution/administration: Reconstor injection, USP. Administer via an infusion bag. For doses <1800 mg, use a 100 mt. bag. For One Mursing orders: Provide skilled nursing visit and assess patient (required for home infusions bag.)	Fax Facility tax ID # specialty pharmacy benefit or home infusion) injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosin ation for additional instruction. Week 3: mg (20 mg/kg) 21-day supply; 1 prescription; 6 refills; q3wk Patient is Medically Urgent. Medically Urgent means the patient both (1) is experiencing compressive optic neuropathy secondary to Thyroid Eye Disease and (2) requires accelerated treatment with TEPEZZA. No known drug allergies (NKDA) Authorize administration supplies as nee stitute each vial with 10 mL of sterile water containing 0.9% sodium chloride solution, r doses ≥1800 mg, use a 250 mL bag. to administer medication, provide education, ion). ase see certification language on the next page)
PRESCRIPTION INFORMATION (Required for Medication: TEPEZZA* (teprotumumab-trbw) for Duration: 1 infusion every 3 weeks for a total of 8 90 minutes. Subsequent infusions may be reduce and Administration section of Prescribing Inform. Dose*: Week 0: mg (10 mg/kg) 21-day supply; 1 prescription; no refill Weight*: kg lbs Allergies*: or Route of administration: Peripheral IV Fluids for reconstitution/administration: Recons for injection, USP. Administer via an infusion bag USP. For doses <1800 mg, use a 100 mL bag. For Mursing orders: Provide skilled nursing visit and assess patient (required for home infus PRESCRIBER CERTIFICATION (Required—ple	Fax Facility tax ID # specialty pharmacy benefit or home infusion) injection, for intravenous use // 500-mg vial infusions. Administer the first 2 infusions over d to 60 minutes, if tolerated. Please see Dosin ation for additional instruction. Week 3: mg (20 mg/kg) 21-day supply; 1 prescription; 6 refills; q3wk Patient is Medically Urgent. Medically Urgent means the patient both (1) is experiencing compressive optic neuropathy secondary to Thyroid Eye Disease and (2) requires accelerated treatment with TEPEZZA. No known drug allergies (NKDA) Authorize administration supplies as nee stitute each vial with 10 mL of sterile water containing 0.9% sodium chloride solution, r doses ≥1800 mg, use a 250 mL bag. to administer medication, provide education, ion). ase see certification language on the next page)

Prescriber Certification

Please read and provide signature in Prescriber Certification section on page 1

I certify that the above therapy is medically necessary, that the information provided is accurate to the best of my knowledge and that my patient is being administered TEPEZZA (teprotumumab-trbw), for intravenous infusion in accordance with the labeled use of the product. I understand that Horizon Therapeutics USA, Inc. and its affiliates and their respective employees or agents (collectively, "Horizon") will use this information to administer the Horizon By Your Side program (the "Program"), which provides a wide array of patient-focused services, including providing logistical and non-medical treatment support for TEPEZZA, as prescribed, and educating about the insurance process. I authorize these parties to act on my behalf for the limited purposes of transmitting this prescription by facsimile to the appropriate pharmacy designated by the patient utilizing their benefit plan. By my signature, I also certify that (1) my patient or his/her personal representative has provided a signed HIPAA authorization that allows me to share protected health information with Horizon for purposes of the Program and (2) I have obtained the patient's authorization to release such information as may be required for AllCare Plus Pharmacy (or another party acting on behalf of Horizon) to assess insurance coverage for TEPEZZA and assistance in initiating or continuing TEPEZZA as prescribed. I further understand and agree that (a) any medication or service provided through the Program as a result of this form is for the named patient only and is not being made in exchange for any express or implied agreement or understanding that I would recommend, prescribe, or use TEPEZZA or any other Horizon product or service, for any other person; (b) my decision to prescribe TEPEZZA was based solely on my professional determination of medical necessity; and (c) I will not seek reimbursement for any medication or service provided by or through the Program from any government program or third-party insurer. I understand that Horizon may modif

State requirements: The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to the prescriber.

By filling out and signing this form, the enrollment process in Horizon By Your Side has initiated; however, your patient must sign a Patient Authorization to complete enrollment in Horizon By Your Side. Please note that your patient will not benefit from the services and support offered by the Program unless your patient signs a Patient Authorization, consenting such services. If your patient does not sign the Patient Authorization contained within this form, Horizon will contact the patient to determine whether the patient is interested in signing a separate Patient Authorization.

Patient Consent for Patient Information, Enrolling in Services, and Accessing Financial Support (referred to as "Patient Authorization")

Please read and provide signature in Patient Authorization section on page 1

I hereby authorize my healthcare providers, my health insurance carriers, and my pharmacies to use and disclose my individually identifiable health information, including my medical records, insurance coverage information, and my name, address, and telephone number to Horizon Therapeutics USA, Inc. and its affiliates and their respective agents and representatives (collectively, "Horizon"), including price authorized by Horizon to administer drug support and to dispense drugs (collectively, "Horizon By Your Side") for the following purposes: (1) to establish eligibility for benefits; (2) to communicate with my healthcare providers and me about my treatment or condition and related products; (3) to facilitate the provision of products, supplies, or services by a third party including, but not limited to, specialty pharmacies; (4) to register me in any applicable product registration program required for my treatment; (5) to enroll me in eligible patient support programs offered by Horizon By Your Side and/or Horizon, including nursing or patient access support services (government-reimbursed programs may not be eligible for all support services offered; please contact Horizon By Your Side for determination); and (6) to send me marketing information or offer me products and services related to my treatment or condition (or other products or services in which imformation or offer me products and services related to my treatment or condition, or my experience with Horizon and/or Horizon By Your Side otherwise as required or permitted by law. Further, I appoint the Program, on my behalf, to proceed with Program services and to convey this prescription to the dispensing pharmacy, to the extent permitted under state law. I understand the pharmacies may receive a fee from Horizon in exchange for (1) providing me with certain materials and information described above, and (2) using or disclosing certain health information pursuant to this Authorization.

I understand that Horizon, as well as my healthcare providers, cannot require me, as a condition of having access to medications, prescription drugs, treatment, or other care, to sign this Authorization. I understand that I am entitled to a copy of this Authorization.

I understand that information disclosed pursuant to this Authorization in some cases may be redisclosed by the recipient and no longer protected by HIPAA or other privacy laws. But Horizon has agreed to use and disclose my information only for purposes of operating the Program. I understand that I may cancel this Authorization at any time by mailing a signed letter requesting such cancellation to Horizon By Your Side, 1 Horizon Way, Deerfield, IL 60015, but that this cancellation will not apply to any information used or disclosed by my healthcare providers and/or health insurance carriers based on this Authorization before they are notified that I have cancelled it. Unless required by state law, this Authorization is valid for whichever is greater: (a) the duration remaining on this treatment or (b) 10 years from the date signed on page 1. A photocopy of this Authorization will be treated in the same manner as the original.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, and menstrual disorders.

For additional information on TEPEZZA, please see Full Prescribing Information at TEPEZZAhcp.com.



